| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
We reported recently that exposure of hamster V79 fibroblasts to 6 drugs that varied in their ability to produce DNA double-strand breaks stimulated formation of phosphorylated histone H2AX (serine 139 phosphorylated histone H2AX; 
H2AX). Using flow cytometry to analyze H2AX antibody-stained cells 1 h after a 30-min drug treatment, the fraction of cells that showed the control levels of H2AX correlated well with the fraction of cells that survived to form colonies. This observation is now extended to V79 and SiHa human cervical carcinoma cells grown as multicell spheroids and SiHa xenografts and SCCVII tumors in mice. Animals were injected with etoposide, a topoisomerase-II inhibitor that targets proliferating cells or 3-amino-1,2,4-benzotriazine-1,3-dioxide (tirapazamine), a bioreductive cytotoxin that targets hypoxic cells. For spheroids, H2AX intensity predicted clonogenic cell survival for cells recovered 90 min after drug injection, regardless of position of the cells within the spheroid. Similar results were obtained for etoposide in tumors; however, the H2AX signal for tirapazamine was smaller than expected for the observed amount of cell killing. Frozen sections of tumors confirmed the greater intensity of H2AX staining in cells close to blood vessels of tumors soon after treatment with etoposide and the opposite pattern for tumors exposed to tirapazamine. Analysis of cells or frozen sections from mouse spleen and kidney suggests that information can also be obtained on initial damage in normal tissues. These results support the possibility of using H2AX antibody staining as a method to aid in prediction of tumor and normal tissue response to treatment.
This article has been cited by other articles:
|
|
 |
|
  X. Liu, E. K. Han, M. Anderson, Y. Shi, D. Semizarov, G. Wang, T. McGonigal, L. Roberts, L. Lasko, J. Palma, et al. Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways Mol. Cancer Res., October 1, 2009; 7(10): 1686 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Rube, S. Grudzenski, M. Kuhne, X. Dong, N. Rief, M. Lobrich, and C. Rube DNA Double-Strand Break Repair of Blood Lymphocytes and Normal Tissues Analysed in a Preclinical Mouse Model: Implications for Radiosensitivity Testing Clin. Cancer Res., October 15, 2008; 14(20): 6546 - 6555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, Y. Shi, R. Guan, C. Donawho, Y. Luo, J. Palma, G.-d. Zhu, E. F. Johnson, L. E. Rodriguez, N. Ghoreishi-Haack, et al. Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks Mol. Cancer Res., October 1, 2008; 6(10): 1621 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ewald, D. Sampath, and W. Plunkett H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation Mol. Cancer Ther., April 1, 2007; 6(4): 1239 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. O. Hicks, F. B. Pruijn, T. W. Secomb, M. P. Hay, R. Hsu, J. M. Brown, W. A. Denny, M. W. Dewhirst, and W. R. Wilson Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst, August 16, 2006; 98(16): 1118 - 1128. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
